These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 2697402)

  • 21. [Phase III clinical trial on domestic amsacrine in patients with acute leukemias].
    Zhonghua Xue Ye Xue Za Zhi; 1997 Feb; 18(2):61-4. PubMed ID: 15622778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
    Richel DJ; Colly LP; Kluin-Nelemans JC; Willemze R
    Br J Cancer; 1991 Jul; 64(1):144-8. PubMed ID: 1713050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amsacrine evaluation.
    Van Mouwerik TJ; Caines PM; Ballentine R
    Drug Intell Clin Pharm; 1987 Apr; 21(4):330-4. PubMed ID: 3552546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
    Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.
    Ferrara F; Palmieri S; Mele G
    Haematologica; 2004 Aug; 89(8):998-1008. PubMed ID: 15339685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New drugs in the treatment of acute and chronic leukaemia: current role of mAMSA.
    Jehn U
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():53-8. PubMed ID: 2697402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA.
    Jehn U; Heinemann V
    Anticancer Res; 1991; 11(2):705-11. PubMed ID: 2064323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of amsacrine, an investigational antineoplastic agent.
    Grove WR; Fortner CL; Wiernik PH
    Clin Pharm; 1982; 1(4):320-6. PubMed ID: 6764391
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.